1-9 of 9
Richard J. Edmondson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib

Free
Aiste McCormick, Peter Donoghue, Michelle Dixon, Richard O’Sullivan, Rachel L. O’Donnell, James Murray, Angelika Kaufmann, Nicola J. Curtin, Richard J. Edmondson
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (16): 3640.
https://doi.org/10.1158/1078-0432.CCR-24-2051
Published: 15 August 2024
View articletitled, Correction: Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib
Open the PDF for Correction: Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib in another window
Journal Articles

Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Available to Purchase
Robert D. Morgan, Andrew R. Clamp, Daniel J. White, Marcus Price, George J. Burghel, W. David J. Ryder, Reem D. Mahmood, Alexander D. Murphy, Jurjees Hasan, Claire L. Mitchell, Zena Salih, Chelsey Wheeler, Emma Buckley, Joanna Truelove, Georgia King, Yasmina Ainaoui, Sanjeev S. Bhaskar, Joseph Shaw, D. Gareth R. Evans, Bedirhan Kilerci, Simon P. Pearce, Gerard Brady, Caroline Dive, James P.B. O'Connor, Andrew J. Wallace, Dominic G. Rothwell, Richard J. Edmondson, Gordon C. Jayson
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (14): 2602–2611.
https://doi.org/10.1158/1078-0432.CCR-22-3282
Published: 14 July 2023
View articletitled, Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
Open the PDF for Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial in another window
Includes: Supplementary data
Journal Articles

Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib

Available to Purchase
Aiste McCormick, Peter Donoghue, Michelle Dixon, Richard O'Sullivan, Rachel L. O'Donnell, James Murray, Angelika Kaufmann, Nicola J. Curtin, Richard J. Edmondson
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (8): 2050–2060.
https://doi.org/10.1158/1078-0432.CCR-16-0564
Published: 13 April 2017
View articletitled, Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib
Open the PDF for Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib in another window
Includes: Supplementary data
Journal Articles

Abstract B9: PTEN expression level is important in determining sensitivity to cytotoxic agents in vitro, but is not representative of PTEN function observed in primary ovarian cancer cultures

Free
Aiste McCormick, Eleanor Earp, Charlotte Leeson, Michelle Dixon, Rachel ODonnell, Richard J. Edmondson
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): B9.
https://doi.org/10.1158/1078-0432.OVCA13-B9
Published: 13 May 2014
View articletitled, Abstract B9: PTEN expression level is important in determining sensitivity to cytotoxic agents in vitro, but is not representative of PTEN function observed in primary ovarian cancer cultures
Journal Articles

Abstract A33: Therapeutic potential of sapacitabine in ovarian cancers defective in homologous recombination

Free
Rachel L. O'Donnell, James CC Murray, Adriana GB Buskin, Sheelagh Frame, David G. Blake, Michelle Dixon, Aiste McCormick, Angelika Kaufmann, E Ruth Plummer, Richard J. Edmondson, Nicola J. Curtin
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): A33.
https://doi.org/10.1158/1078-0432.OVCA13-A33
Published: 13 May 2014
View articletitled, Abstract A33: Therapeutic potential of sapacitabine in ovarian cancers defective in homologous recombination
Journal Articles

Abstract PR06: Ovarian cancers harbor defects in nonhomologous end joining resulting in error prone repair and resistance to rucaparib

Free
Aiste McCormick, Michelle Dixon, Rachel ODonnell, Nicola J. Curtin, Richard J. Edmondson
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): PR06.
https://doi.org/10.1158/1078-0432.OVCA13-PR06
Published: 13 May 2014
View articletitled, Abstract PR06: Ovarian cancers harbor defects in nonhomologous end joining resulting in error prone repair and resistance to rucaparib
Journal Articles

Abstract PR10: Intra- and intertumor heterogeneity in epithelial ovarian cancer: Consequences for biomarker-dependent stratification of therapies

Free
Rachel L. O'Donnell, Laura C. Woodhouse, Aiste McCormick, Angelika Kaufmann, Michelle Dixon, Asima Mukhopadhyay, Nicola J. Curtin, Richard J. Edmondson
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): PR10.
https://doi.org/10.1158/1078-0432.OVCA13-PR10
Published: 13 May 2014
View articletitled, Abstract PR10: Intra- and intertumor heterogeneity in epithelial ovarian cancer: Consequences for biomarker-dependent stratification of therapies
Journal Articles

Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

Available to Purchase
Asima Mukhopadhyay, Ahmed Elattar, Aiste Cerbinskaite, Sarah J. Wilkinson, Yvette Drew, Suzanne Kyle, Gerrit Los, Zdenek Hostomsky, Richard J. Edmondson, Nicola J. Curtin
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (8): 2344–2351.
https://doi.org/10.1158/1078-0432.CCR-09-2758
Published: 14 April 2010
View articletitled, Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
Open the PDF for Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors in another window
Includes: Supplementary data
Journal Articles

NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism

Available to Purchase
David Jamieson, Kerrie Wilson, Simon Pridgeon, Jane P. Margetts, Richard J. Edmondson, Hing Y. Leung, Richard Knox, Alan V. Boddy
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (5): 1584–1590.
https://doi.org/10.1158/1078-0432.CCR-06-1416
Published: 01 March 2007
View articletitled, NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism
Open the PDF for NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism in another window